L. De Rosa

发表

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

M. Boccadoro, V. Callea, S. Ferrero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

G. Avvisati, G. Cimino, F. Stocchi, 2020, Journal of bone oncology.

Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.

P. Iudicone, M. Guglielmetti, V. Zoli, 1995, Journal of hematotherapy.

Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission

R. Amodeo, L. De Rosa, M. Lalle, 2002, Annals of Hematology.

Autologous Blood Stem Cell Collection after Chemotherapy in Patients with Sensitive and Refractory Malignancies: A Multicenter Retrospective Study

G. Leone, A. Nicolucci, L. Pierelli, 1993, The International journal of artificial organs.

Autologous blood stem cell transplantation in malignant lymphomas: an Italian Cooperative Study.

L. Pierelli, G. Fioritoni, R. Scimé, 1992, Leukemia & lymphoma.

Growth factor administration following autologous peripheral blood progenitor cell transplantation.

G. Leone, G. Scambia, L. Pierelli, 1997, Leukemia & lymphoma.

Efficacy of Imatinib Mesylate in a Patient with Idiopathic Hypereosinophilic Syndrome and Severe Heart Involvement

I. Majolino, L. De Rosa, M. Riccardi, 2005, Tumori.

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

A. Tafuri, A. Siniscalchi, M. Petrucci, 2022, EJHaem.

Successful paternity with microassisted fertilization after total body irradiation-based conditioning for autologous bone marrow transplantation.

G. Metro, I. Majolino, B. Villaccio, 2003, The hematology journal : the official journal of the European Haematology Association.

Progenitor Cells Purging: Negative Selection

A. Montuoro, L. De Rosa, A. Pandolfi, 1993, The International journal of artificial organs.

Cyclophosphamide’s addition in relapsed/refractory multiple myeloma patients with biochemical progression during lenalidomide‐dexamethasone treatment

A. Siniscalchi, M. Petrucci, T. Za, 2018, European journal of haematology.

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

M. Boccadoro, L. Trusolino, A. Bertotti, 2014, British journal of haematology.

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

V. Pavone, M. Boccadoro, A. Santoro, 2019, Haematologica.

A technique for isolation of bone marrow cells using hydroxyethyl starch (HES) sedimentation agent.

A. Montuoro, L. De Rosa, A. Pandolfi, 1991, Haematologica.

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

M. Dimopoulos, P. Sonneveld, M. Boccadoro, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

S. Rutella, R. De Cristofaro, A. Procoli, 2012, Journal of Translational Medicine.

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

M. Boccadoro, D. Rossi, G. Gaidano, 2010, Blood.

Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form

G. Cimino, V. De Stefano, S. Felici, 2012, Cancer.

Primary Cutaneous Follicle Center Cell Lymphoma and Limited Stage Follicular Non-Hodgkin's Lymphoma: A Comparison of Clinical and Biological Features

A. Pulsoni, L. De Rosa, G. Anghel, 2002, Leukemia & lymphoma.

Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.

A. Montuoro, L. De Rosa, A. De Laurenzi, 1992, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party.

M. Labopin, D. Blaise, A. Nagler, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.

V. Pavone, M. Boccadoro, R. Mina, 2022, The Lancet. Oncology.

Detection of Breast Cancer Cells in the Bone Marrow or Peripheral Blood: Methods and Prognostic Significance

A. Montuoro, L. De Rosa, M. Lalle, 2000, Tumori.

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

S. Rutella, F. Locatelli, G. Scambia, 2012, Journal of Translational Medicine.

Immune recovery in breast cancer patients after tandem high-dose chemotherapy rescued by selected CD34+ cells.

R. Amodeo, A. Montuoro, L. De Rosa, 2002, Journal of hematotherapy & stem cell research.

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group

G. Cimino, V. De Stefano, A. Siniscalchi, 2021, Annals of Hematology.

Alpha‐2a‐interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma

A. Montuoro, L. De Rosa, L. Pacilli, 1990, British journal of haematology.

Expression of natural killer (NK) antigens in malignant histiocytosis and a subset of acute myelomonocytic leukaemias.

V. Zagonel, A. Carbone, A. Pinto, 1989, Bone Marrow Transplantation.